Common Laboratory Mice Are Susceptible to Infection with the SARS-CoV-2 Beta Variant by Ravi Kant, Lauri Kareinen, Teemu Smura, Tobias L. Freitag, Sawan Kumar Jha, Kari Alitalo, Seppo Meri, Tarja Sironen, Kalle Saksela, Tomas Strandin, Anja Kipar, Olli Vapalahti

Subjects: Get full text

Reverse Transcription Polymerase Chain Reaction Pattern of SARS-CoV-2 Beta Variant by Daniela Fonseca e Silva, Paulo Dias Silva, Inês Baldaque

Get full text

Correlation between Commercial Anti-RBD IgG Titer and Neutralization Titer against SARS-CoV-2 Beta Variant by Rosana Wing-Shan Poon, Lu Lu, Carol Ho-Yan Fong, Tak-Chuen Ip, Lin-Lei Chen, Ricky Rui-Qi Zhang, Cyril Chik-Yan Yip, Vincent Chi-Chung Cheng, Kwok-Hung Chan, Kwok-Yung Yuen, Kelvin Kai-Wang To

Get full text

BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant by Ludwig Knabl, Hye Kyung Lee, Manuel Wieser, Anna Mur, August Zabernigg, Ludwig Knabl, Simon Rauch, Matthias Bock, Jana Schumacher, Norbert Kaiser, Priscilla A. Furth, Lothar Hennighausen

“…Knabl and Lee et al. use RNA sequencing to assess the impact of vaccination with BNT162b2 on the peripheral innate immune response of a small cohort of COVID-19 patients infected with the SARS-CoV-2 Beta variant. They show an increased JAK-STAT-mediated immune response in vaccinated patients as compared to unvaccinated ones.…”
Get full text

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant by Carlos Ávila-Nieto, Júlia Vergara-Alert, Júlia Vergara-Alert, Pep Amengual-Rigo, Erola Ainsua-Enrich, Marco Brustolin, Marco Brustolin, María Luisa Rodríguez de la Concepción, Núria Pedreño-Lopez, Jordi Rodon, Jordi Rodon, Victor Urrea, Edwards Pradenas, Silvia Marfil, Ester Ballana, Ester Ballana, Ester Ballana, Eva Riveira-Muñoz, Mònica Pérez, Mònica Pérez, Núria Roca, Núria Roca, Ferran Tarrés-Freixas, Julieta Carabelli, Guillermo Cantero, Guillermo Cantero, Anna Pons-Grífols, Carla Rovirosa, Carmen Aguilar-Gurrieri, Raquel Ortiz, Ana Barajas, Benjamin Trinité, Rosalba Lepore, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, Nuria Izquierdo-Useros, Nuria Izquierdo-Useros, Nuria Izquierdo-Useros, Alfonso Valencia, Alfonso Valencia, Julià Blanco, Julià Blanco, Julià Blanco, Julià Blanco, Bonaventura Clotet, Bonaventura Clotet, Bonaventura Clotet, Bonaventura Clotet, Bonaventura Clotet, Victor Guallar, Victor Guallar, Joaquim Segalés, Joaquim Segalés, Jorge Carrillo, Jorge Carrillo, Jorge Carrillo

“…Therefore, the higher yield of S-29, as well as its improved immunogenicity and efficacy protecting from the highly pathogenic SARS-CoV-2 Beta variant, pinpoint the S-29 mutant as an alternative to the S-2P protein for future SARS-CoV-2 vaccine development.…”
Get full text

Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose boosterResearch in context by Terry M. Nolan, Georgia Deliyannis, Maryanne Griffith, Sabine Braat, Lilith F. Allen, Jennifer Audsley, Amy W. Chung, Marcin Ciula, Nicholas A. Gherardin, Michelle L. Giles, Tom P. Gordon, Samantha L. Grimley, Lana Horng, David C. Jackson, Jennifer A. Juno, Katherine Kedzierska, Stephen J. Kent, Sharon R. Lewin, Mason Littlejohn, Hayley A. McQuilten, Francesca L. Mordant, Thi H.O. Nguyen, Vanessa Pac Soo, Briony Price, Damian F.J. Purcell, Pradhipa Ramanathan, Samuel J. Redmond, Steven Rockman, Zheng Ruan, Joseph Sasadeusz, Julie A. Simpson, Kanta Subbarao, Stewart A. Fabb, Thomas J. Payne, Asuka Takanashi, Chee Wah Tan, Joseph Torresi, Jing Jing Wang, Lin-Fa Wang, Hareth Al-Wassiti, Chinn Yi Wong, Sophie Zaloumis, Colin W. Pouton, Dale I. Godfrey

“…This Phase I trial evaluated two vaccines targeting SARS-CoV-2 beta-variant receptor-binding domain (RBD): a recombinant dimeric RBD-human IgG1 Fc-fusion protein, and an mRNA encoding a membrane-anchored RBD. …”
Get full text

A bivalent subunit vaccine efficiently produced in Pichia pastoris against SARS-CoV-2 and emerging variants by Huifang Xu, Tiantian Wang, Peng Sun, Xuchen Hou, Xin Gong, Bin Zhang, Jun Wu, Bo Liu

“…In this study, the receptor binding domain (RBD) of the SARS-CoV-2 Beta variant was successfully expressed through a glycoengineered yeast platform. …”
Get full text

Computational redesign of Beta-27 Fab with substantially better predicted binding affinity to the SARS-CoV-2 Omicron variant than human ACE2 receptor by Wantanee Treewattanawong, Thassanai Sitthiyotha, Surasak Chunsrivirot

“…Previous study found that Beta-27 Fab, which was obtained by digesting the full IgG antibodies that were isolated from a patient infected with SARS-CoV-2 Beta variant, can neutralize Victoria, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) variants. …”
Get full text

Fast and Accurate Surrogate Virus Neutralization Test Based on Antibody-Mediated Blocking of the Interaction of ACE2 and SARS-CoV-2 Spike Protein RBD by Denis E. Kolesov, Maria V. Sinegubova, Lutsia K. Dayanova, Inna V. Dolzhikova, Ivan I. Vorobiev, Nadezhda A. Orlova

“…For the RBD, bearing three amino acid substitutions and corresponding to the SARS-CoV-2 beta variant, the inhibitory strength was diminished for 18 out of 20 randomly chosen serum samples, and the magnitude of this decrease was not similar to the change in overall anti-RBD IgG level. …”
Get full text

A universal SARS‐CoV DNA vaccine inducing highly cross‐reactive neutralizing antibodies and T cells by Sofia Appelberg, Gustaf Ahlén, Jingyi Yan, Negin Nikouyan, Sofie Weber, Olivia Larsson, Urban Höglund, Soo Aleman, Friedemann Weber, Emma Perlhamre, Johanna Apro, Eva‐Karin Gidlund, Ola Tuvesson, Simona Salati, Matteo Cadossi, Hanna Tegel, Sophia Hober, Lars Frelin, Ali Mirazimi, Matti Sällberg

“…The vaccine protected mice carrying the human ACE2 receptor against lethal infection with the SARS‐CoV‐2 Beta variant. Interestingly, priming of cross‐reactive nucleoprotein‐specific T cells alone was 60% protective, verifying observations from humans that T cells protect against lethal disease. …”
Get full text

Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus by Limin S. Ding, Limin S. Ding, Yuhang Zhang, Yuhang Zhang, Dan Wen, Dan Wen, Jianbo Ma, Hao Yuan, Hao Yuan, Hongyue Li, Hongyue Li, Shuguang Duo, Fei Yuan, Yong E. Zhang, Yong E. Zhang, Yong E. Zhang, Aihua Zheng, Aihua Zheng, Aihua Zheng

“…A single dose of rVSV-SARS-CoV-2 Beta variant could elicit enhanced and broad-spectrum neutralizing antibody responses in human ACE2 knock-in mice and golden Syrian hamsters, while other mutants generated antibody levels comparable to the wild-type. …”
Get full text

Immunological and Pathological Peculiarity of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant by Sunhee Lee, Gun Young Yoon, Su Jin Lee, Young-Chan Kwon, Hyun Woo Moon, Yu-Jin Kim, Haesoo Kim, Wooseong Lee, Gi Uk Jeong, Chonsaeng Kim, Kyun-Do Kim, Seong-Jun Kim, Dae-Gyun Ahn

“…We investigated the immunological and pathological peculiarity of the SARS-CoV-2 beta variant of concern (VoC) compared to the ancestral strain. …”
Get full text

Single-Dose Intranasal Immunisation with Novel Chimeric H1N1 Expressing the Receptor-Binding Domain of SARS-CoV-2 Induces Robust Mucosal Immunity, Tissue-Resident Memory T Cells, a... by Donghong Wang, Yao Deng, Jianfang Zhou, Wen Wang, Baoying Huang, Wenling Wang, Lan Wei, Jiao Ren, Ruiwen Han, Jialuo Bing, Chengcheng Zhai, Xiaoyan Guo, Wenjie Tan

“…Importantly, immunisation with PR8NARBD/WSN viruses effectively protected mice against lethal challenges with H1N1, H3N2 IAV, and SARS-CoV-2 Beta variant and significantly reduced lung viral loads. …”
Get full text

Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters by Benjamin Vesin, Pierre Authié, Catherine Blanc, Ingrid Fert, Amandine Noirat, Fabien Le Chevalier, Yu Wei, Min-Wen Ku, Kirill Nemirov, François Anna, David Hardy, Cyril Planchais, Hugo Mouquet, Françoise Guinet, Pierre Charneau, Laleh Majlessi, Maryline Bourgine

“…In addition, we show that a lentiviral vector encoding stabilized Spike of SARS-CoV-2 Beta variant (LV::S_Beta-2P) prevents pathology and reduces infectious viral loads in lungs and nasal turbinates following inoculation with the SARS-CoV-2 Omicron variant. …”
Get full text

Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates by Patricia Pérez, Patricia Pérez, Guillermo Albericio, David Astorgano, Sara Flores, Cristina Sánchez-Corzo, Pedro J. Sánchez-Cordón, Joanna Luczkowiak, Joanna Luczkowiak, Rafael Delgado, Rafael Delgado, Rafael Delgado, José M. Casasnovas, Mariano Esteban, Juan García-Arriaza, Juan García-Arriaza

“…Preclinical evaluation of MVA-S(3Pbeta) in head-to-head comparison to the previously generated MVA-S(3P) vaccine candidate, expressing a full-length prefusion-stabilized Wuhan S protein (with also 3P substitutions), demonstrated that two intramuscular doses of both vaccine candidates fully protected transgenic K18-hACE2 mice from a lethal challenge with SARS-CoV-2 beta variant, reducing mRNA and infectious viral loads in the lungs and in bronchoalveolar lavages, decreasing lung histopathological lesions and levels of proinflammatory cytokines in the lungs. …”
Get full text

Specific CD4+ T Cell Responses to Ancestral SARS-CoV-2 in Children Increase With Age and Show Cross-Reactivity to Beta Variant by Kevin Paul, Kevin Paul, Freya Sibbertsen, Daniela Weiskopf, Marc Lütgehetmann, Marc Lütgehetmann, Madalena Barroso, Marta K. Danecka, Laura Glau, Laura Hecher, Katharina Hermann, Aloisa Kohl, Jun Oh, Julian Schulze zur Wiesch, Julian Schulze zur Wiesch, Alessandro Sette, Alessandro Sette, Eva Tolosa, Eik Vettorazzi, Mathias Woidy, Mathias Woidy, Antonia Zapf, Dimitra E. Zazara, Dimitra E. Zazara, Thomas S. Mir, Ania C. Muntau, Søren W. Gersting, Gabor A. Dunay, Gabor A. Dunay

“…Cross-reactive T cells for the SARS-CoV-2 beta variant were identified in 45% of cases after infection with an ancestral SARS-CoV-2 variant. …”
Get full text